New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.
MS affects at least twice as many more women than men, and it often strikes at an age when many people are thinking about starting or growing their families.
Studies show that improved MS medications and advances in MRI technology have led to an increased rate of doctors changing courses of MS treatment and a reduced tolerance of any sign of disease activity, with doctors more readily switching treatments in cases of low disease activity.
How the biological processes cause progression in different types of MS.
Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS
A new, international clinical trial has shown that siponimod can slow progression in people with secondary progressive MS.
Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.
The EMA has recommended that ocrelizumab (Ocrevus), the first disease-modifying treatment for primary progressive MS (PPMS), be prescribed for adults with early primary progressive MS
Prof. Sørensen, one of the world’s prominent clinical neurologists in multiple sclerosis, recognised for lifetime achievement in improving understanding and treatment of MS.